Toni K. Choueiri, MD, on Renal Cell Carcinoma: Follow-up Data on Pembrolizumab
2022 ASCO Genitourinary Cancers Symposium
Toni K. Choueiri, MD, of Dana-Farber Cancer Institute, discusses a 30-month follow-up of results from the KEYNOTE-564 trial, which further support the use of adjuvant pembrolizumab when treating patients with renal cell carcinoma at intermediate-high or high risk of recurrence, or with an M1 NED (no evidence of disease) status after nephrectomy. The data show a disease-free survival benefit vs placebo (Abstract 290).
The ASCO Post Staff
Alfredo Berruti, MD, of Italy’s University of Brescia, discusses the first study to give adjuvant mitotane to patients with adrenocortical carcinoma, a rare disease with a high risk of relapse after radical surgery. Although theoretically this treatment may be clinically worthwhile, the findings suggest that the need for adjuvant mitotane should always be discussed on a case-by-case basis by the multidisciplinary team, and more study is warranted (Abstract 1).
The ASCO Post Staff
Petros Grivas, MD, PhD, of the University of Washington and Fred Hutchinson Cancer Research Center, discusses results from Cohort 3 of the TROPHY-U-01 study, which assessed sacituzumab govitecan-hziy in combination with pembrolizumab in patients with metastatic urothelial cancer who experienced disease progression after platinum-based regimens (Abstract 434).
The ASCO Post Staff
Simon J. Crabb, PhD, MBBS, of the Southampton Experimental Cancer Medicine Centre, discusses data from the ATLANTIS trial, in which the authors hypothesized that switch maintenance therapy with the PARP inhibitor rucaparib, in patients who have derived clinical benefit from first-line chemotherapy, may improve outcomes for those with metastatic urothelial carcinoma that harbored a composite biomarker for DNA repair deficiency (Abstract 436).
The ASCO Post Staff
Alicia K. Morgans, MD, MPH, of Dana-Farber Cancer Institute, discusses findings from the largest digital survey conducted in patients with prostate cancer, allowing identification of unmet needs in the patient journey. Preliminary data suggest that lower rates of screening may correlate with higher rates of symptoms at diagnosis and potentially later-stage diagnosis.
The ASCO Post Staff
Karen E. Knudsen, PhD, MBA, Chief Executive Officer of the American Cancer Society, discusses ways to address the inequities in genitourinary screening, treatment, and outcomes. Her suggestions focus on increasing awareness of screening, identifying risk factors, the dramatic rise in incidence among Hispanic individuals, and the basis for increased mortality in Black men.